Arhgap18: An endogenous inhibitor of angiogenesis, limiting tip formation and stabilizing junctions

Small GTPases

Volumn 5, Issue 3, 2014, Pages

  Chang, Garry Hk ^a,c   Lay, Angelina J ^a,c   Ting, Ka Ka ^a,c   Zhao, Yang ^a,c   Coleman, Paul R ^a,c   Powter, Elizabeth E ^a,c   Formaz Preston, Ann ^a,c   Jolly, Christopher J ^a,c   Bower, Neil I ^b   Hogan, Benjamin M ^b   Rinkwitz, Silke ^c   Becker, Thomas S ^c   Vadas, Mathew A ^a,c   Gamble, Jennifer R ^a,c  

^a CENTENARY INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Angiogenesis; ARHGAP18; Cell junctions; SENEX; Sprouting

Indexed keywords

ANGIOGENESIS INHIBITOR; PROTEIN RHOC; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ARHGAP18 PROTEIN, HUMAN; ARHGAP18 PROTEIN, MOUSE; ARHGAP18 PROTEIN, ZEBRAFISH; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; ZEBRAFISH PROTEIN;

ADULT; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARHGAP18 GENE; ARTICLE; CELL JUNCTION; CELL MATURATION; CELL MIGRATION; CELL SPROUTING; CONTROLLED STUDY; DLL4 GENE; EMBRYO; ENDOTHELIUM CELL; FEMALE; FLK1 GENE; FLT4 GENE; GENE; GENE DELETION; GENE LOCATION; GENE LOSS; GENE SILENCING; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; MELANOMA; MOUSE; MURINAE; NONHUMAN; PHENOTYPE; RETINA BLOOD VESSEL; SUBCUTANEOUS TISSUE TUMOR; TIP CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; VASCULAR RING; WILD TYPE; ZEBRA FISH; ANIMAL; C57BL MOUSE; CYTOLOGY; EMBRYOLOGY; EXPERIMENTAL MELANOMA; GENETICS; METABOLISM; PATHOLOGY; RETINA; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULARIZATION;

DANIO RERIO; MURINAE;

ANIMALS; CELL LINE, TUMOR; ENDOTHELIAL CELLS; GTPASE-ACTIVATING PROTEINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERCELLULAR JUNCTIONS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; RETINA; RHO GTP-BINDING PROTEINS; ZEBRAFISH; ZEBRAFISH PROTEINS;

EID: 84922221555     PISSN: 21541248     EISSN: 21541256     Source Type: Journal    
DOI: 10.4161/21541248.2014.975002     Document Type: Article

References (55)

1. Herbert SP, Stainier DY. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol 2011; 12:551-64; PMID:21860391; http://dx.doi.org/10.1038/ nrm3176
2. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011; 146:873-87; PMID:21925313; http://dx.doi.org/10.1016/j.cell. 2011.08.039
3. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011; 17:1359-70; PMID:22064426; http://dx.doi.org/10.1038/nm.2537
4. Ware JA, Simons M. Angiogenesis in ischemic heart disease. Nat Med 1997; 3:158-64; PMID:9018233; http://dx.doi.org/10.1038/nm0297-158
5. Marti HH, Risau W. Angiogenesis in ischemic disease. Thromb Haemost 1999; 82 Suppl 1:44-52; PMID: 10695485
6. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473:298-307; PMID:21593862; http://dx.doi.org/10.1038/ nature10144
7. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol cell Biol 2007; 8:464-78; PMID:17522591; http://dx.doi.org/10.1038/nrm2183
8. Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nat 2007; 445:776-80; PMID:17259973; http://dx.doi.org/10.1038/nature05571
9. Jakobsson L, Franco CA, Bentley K, Collins RT, Ponsioen B, Aspalter IM, Rosewell I, Busse M, Thurston G, Medvinsky A, et al. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat Cell Biol 2010; 12:943-53; PMID:20871601; http://dx.doi.org/10.1038/ncb2103
10. Lobov IB, Renard RA, Papadopoulos N, Gale NW, Thurston G, Yancopoulos GD, Wiegand SJ. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative 14 regulator of angiogenic sprouting. Proc Natl Acad Sci U S A 2007; 104:3219-24; PMID:17296940; http://dx.doi.org/10.1073/pnas.0611206104
11. Bentley K, Franco CA, Philippides A, Blanco R, Dierkes M, Gebala V, Stanchi F, Jones M, Aspalter IM, Cagna G, et al. The role of differential VE-cadherin dynamics in cell rearrangement during angiogenesis. Nat cell Biol 2014; 16(4):309-21; PMID:24658686
12. Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol cell Biol 2008; 9:690-701; PMID:18719708; http://dx.doi.org/10.1038/nrm2476
13. Bryan BA, D’Amore PA. What tangled webs they weave: Rho-GTPase control of angiogenesis. Cell Mol life Sci 2007; 64:2053-65; PMID:17530172; http://dx.doi.org/10.1007/s00018-007-7008-z
14. Kim C, Yang H, Fukushima Y, Saw PE, Lee J, Park JS, Park I, Jung J, Kataoka H, Lee D, et al. Vascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption. Cancer Cell 2014; 25:102-17; PMID:24434213; http://dx.doi.org/10.1016/j.ccr.2013.12.010
15. Vega FM, Ridley AJ. Rho GTPases in cancer cell biology. FEBS Lett 2008; 582:2093-101; PMID:18460342; http://dx.doi.org/10.1016/j.febslet.2008.04.039
16. Seasholtz TM, Brown JH. RHO SIGNALING in vascular diseases. Mol Interv 2004; 4:348-57; PMID: 15616164; http://dx.doi.org/10.1124/mi.4.6.8
17. van der Meel R, Symons MH, Kudernatsch R, Kok RJ, Schiffelers RM, Storm G, Gallagher WM, Byrne AT. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy. Drug Discov Today 2011; 16:219-28; PMID:21262381; http://dx.doi.org/10.1016/j.drudis.2011.01.005
18. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer 2002; 2:133-42; PMID:12635176; http://dx.doi.org/10.1038/nrc725
19. Cook DR, Rossman KL, Der CJ. Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease. Oncogene 2014; 33:4021-4035; PMID:24037532; http://dx.doi.org/10.1038/onc.2013.362
20. Xue W, Krasnitz A, Lucito R, Sordella R, Vanaelst L, Cordon-Cardo C, Singer S, Kuehnel F, Wigler M, Powers S, et al. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev 2008; 22:1439-44; PMID:18519636; http://dx.doi.org/10.1101/gad.1672608
21. Ng IO, Liang ZD, Cao L, Lee TK. DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1. Cancer Res 2000; 60:6581-4; PMID:11118037
22. Yuan BZ, Zhou X, Durkin ME, Zimonjic DB, Gumundsdottir K, Eyfjord JE, Thorgeirsson SS, Popescu NC. DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene 2003; 22:445-50; PMID:12545165; http://dx.doi.org/10.1038/sj.onc.1206064
23. Coleman PR, Hahn CN, Grimshaw M, Lu Y, Li X, Brautigan PJ, Beck K, Stocker R, Vadas MA, Gamble JR. Stress-induced premature senescence mediated by a novel gene, SENEX, results in an anti-inflammatory phenotype in endothelial cells. Blood 2010; 116:4016-24; PMID:20664062; http://dx.doi.org/10.1182/blood-2009-11-252700
24. Hahn CN, Su ZJ, Drogemuller CJ, Tsykin A, Waterman SR, Brautigan PJ, Yu S, Kremmidiotis G, Gardner A, Solomon PJ, et al. Expression profiling reveals functionally important genes and coordinately regulated signaling pathway genes during in vitro angiogenesis. Physioll Genomics 2005; 22:57-69; PMID:15840639; http://dx.doi.org/10.1152/physiolgenomics.00278.2004
25. van Buul JD, Geerts D, Huveneers S. Rho GAPs and GEFs: Controling switches in endothelial cell adhesion. Cell Adh Migr 2014; 8:108-124; PMID:24622613; http://dx.doi.org/10.4161/cam.27599
26. Maeda M, Hasegawa H, Hyodo T, Ito S, Asano E, Yuang H, Funasaka K, Shimokata K, Hasegawa Y, Hamaguchi M, et al. ARHGAP18, a GTPase-activating protein for RhoA, controls cell shape, spreading, and motility. Mol Biol Cell 2011; 22:3840-52; PMID:21865595; http://dx.doi.org/10.1091/mbc.E11-04-0364
27. Gariano RF, Gardner TW. Retinal angiogenesis in development and disease. Nature 2005; 438:960-6; PMID: 16355161; http://dx.doi.org/10.1038/nature04482
28. Phng LK, Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev Cell 2009; 16:196-208; PMID:19217422; http://dx.doi.org/10.1016/j.devcel.2009.01.015
29. Rabiet MJ, Plantier JL, Rival Y, Genoux Y, Lampugnani MG, Dejana E. Thrombin-induced increase in endothelial permeability is associated with changes in cell-to-cell junction organization. Arterioscler Thromb Vasc Biol 1996; 16:488-96; PMID:8630677; http://dx.doi.org/10.1161/01.ATV.16.3.488
30. Gamble JR, Drew J, Trezise L, Underwood A, Parsons M, Kasminkas L, Rudge J, Yancopoulos G, Vadas MA. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res 2000; 87:603-7; PMID:11009566; http://dx.doi.org/10.1161/01.RES.87.7.603
31. van Nieuw Amerongen GP, Koolwijk P, Versteilen A, van Hinsbergh VW. Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro. Arterioscler Thromb Vasc Biol 2003; 23:211-7; PMID: http://dx.doi.org/10.1161/01.ATV.0000054198.68894.88
32. Ngok SP, Geyer R, Liu M, Kourtidis A, Agrawal S, Wu C, Seerapu HR, Lewis-Tuffin LJ, Moodie KL, Huveldt D, et al. VEGF and Angiopoietin-1 exert opposing effects on cell junctions by regulating the Rho GEF Syx. J Cell Biol 2012; 199:1103-15; PMID:23253477; http://dx.doi.org/10.1083/jcb.201207009
33. Huveneers S, Oldenburg J, Spanjaard E, van der Krogt G, Grigoriev I, Akhmanova A, Rehmann H, de Rooij J. Vinculin associates with endothelial VE-cadherin junctions to control force-dependent remodeling. J Cell Bioly 2012; 196:641-52; PMID:22391038; http://dx.doi.org/10.1083/jcb.201108120
34. Liu ZJ, Shirakawa T, Li Y, Soma A, Oka M, Dotto GP, Fairman RM, Velazquez OC, Herlyn M. Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol 2003; 23:14-25; PMID:12482957; http://dx.doi.org/10.1128/MCB.23.1.14-25.2003
35. Neisch AL, Formstecher E, Fehon RG. Conundrum, an ARHGAP18 orthologue, regulates RhoA and proliferation through interactions with Moesin. Mol Biol Cell 2013; 24:1420-33; PMID:23468526; http://dx.doi.org/10.1091/mbc.E12-11-0800
36. Akilesh S, Suleiman H, Yu H, Stander MC, Lavin P, Gbadegesin R, Antignac C, Pollak M, Kopp JB, Winn MP, et al. Arhgap24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis. J Clin Invest 2011; 121:4127-37; PMID:21911940; http://dx.doi.org/10.1172/JCI46458
37. Lavelin I, Geiger B. Characterization of a novel GTPase-activating protein associated with focal adhesions and the actin cytoskeleton. J Biol Chem 2005; 280:7178-85; PMID:15611138; http://dx.doi.org/10.1074/jbc.M411990200
38. Su ZJ, Hahn CN, Goodall GJ, Reck NM, Leske AF, Davy A, Kremmidiotis G, Vadas MA, Gamble JR. A vascular cell-restricted RhoGAP, p73RhoGAP, is a key regulator of angiogenesis. Proc Natl Acad Sci U S A 2004; 101:12212-7; PMID:15302923; http://dx.doi.org/10.1073/pnas.0404631101
39. Wheeler AP, Ridley AJ. Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. Exp Cell Res 2004; 301:43-9; PMID:15501444; http://dx.doi.org/10.1016/j.yexcr.2004.08.012
40. Hakem A, Sanchez-Sweatman O, You-Ten A, Duncan G, Wakeham A, Khokha R, Mak TW. RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev 2005; 19:1974-9; PMID:16107613; http://dx.doi.org/10.1101/gad.1310805
41. van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 2000; 60:5832-8; PMID:11059780
42. Simpson KJ, Dugan AS, Mercurio AM. Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma. Cancer Res 2004; 64:8694-701; PMID:15574779; http://dx.doi.org/10.1158/0008-5472.CAN-04-2247
43. Bellovin DI, Simpson KJ, Danilov T, Maynard E, Rimm DL, Oettgen P, Mercurio AM. Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma. Oncogene 2006; 25:6959-67; PMID:16715134; http://dx.doi.org/10.1038/sj.onc.1209682
44. Sahai E, Marshall CJ. ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nat Cell Biol 2002; 4:408-15; PMID:11992112; http://dx.doi.org/10.1038/ncb796
45. Vega FM, Fruhwirth G, Ng T, Ridley AJ. RhoA and RhoC have distinct roles in migration and invasion by acting through different targets. J Cell Biol 2011; 193:655-65; PMID:21576392; http://dx.doi.org/10.1083/jcb.201011038
46. Kitzing TM, Wang Y, Pertz O, Copeland JW, Grosse R. Formin-like 2 drives amoeboid invasive cell motility downstream of RhoC. Oncogene 2010; 29:2441-8; PMID: 20101212; http://dx.doi.org/10.1038/onc.2009.515
47. del Toro R, Prahst C, Mathivet T, Siegfried G, Kaminker JS, Larrivee B, Breant C, Duarte A, Takakura N, Fukamizu A, et al. Identification and functional analysis of endothelial tip cell-enriched genes. Blood 2010; 116:4025-33; PMID:20705756; http://dx.doi.org/10.1182/blood-2010-02-270819
48. Strasser GA, Kaminker JS, Tessier-Lavigne M. Microarray analysis of retinal endothelial tip cells identifies CXCR4 as a mediator of tip cell morphology and branching. Blood 2010; 115:5102-10; PMID: 20154215; http://dx.doi.org/10.1182/blood-2009-07-230284
49. Uebelhoer M, Natynki M, Kangas J, Mendola A, Nguyen HL, Soblet J, Godfraind C, Boon LM, Eklund L, Limaye N, et al. Venous malformation-causative TIE2 mutations mediate an AKT-dependent decrease in PDGFB. Hum Mol Genet 2013; 22:3438-48; PMID:23633549; http://dx.doi.org/10.1093/hmg/ddt198
50. Hu X, Stern HM, Ge L, O’Brien C, Haydu L, Honchell CD, Haverty PM, Peters BA, Wu TD, Amler LC, et al. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res 2009; 7:511-22; PMID:19372580; http://dx.doi.org/10.1158/1541-7786.MCR-08-0107
51. Stefansson OA, Jonasson JG, Olafsdottir K, Bjarnason H, Th Johannsson O, Bodvarsdottir SK, Valgeirsdottir S, Eyfjord JE. Genomic and phenotypic analysis of BRCA2 mutated breast cancers reveals co-occurring changes linked to progression. Breast Cancer Res 2011; 13:R95; PMID:21958427; http://dx.doi.org/10.1186/bcr3020
52. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic acids Res 2011; 39:D945-50; PMID:20952405; http://dx.doi.org/10.1093/nar/gkq929
53. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods 2012; 9:676-82; PMID:22743772; http://dx.doi.org/10.1038/nmeth.2019
54. Baker M, Robinson SD, Lechertier T, Barber PR, Tavora B, D’Amico G, Jones DT, Vojnovic B, Hodivala-Dilke K. Use of the mouse aortic ring assay to study angiogenesis. Nat Protoc 2012; 7:89-104; http://dx.doi.org/10.1038/nprot.2011.435
55. Pitulescu ME, Schmidt I, Benedito R, Adams RH. Inducible gene targeting in the neonatal vasculature and analysis of retinal angiogenesis in mice. Nat Protoc 2010; 5:1518-34; PMID:20725067; http://dx.doi.org/10.1038/nprot.2010.113